Abstract
AdvanTIG-202: A phase 2 study investigating anti-T cell immunoglobulin and ITIM domain monoclonal antibody ociperlimab plus tislelizumab in patients with previously treated recurrent or metastatic cervical cancer (333)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have